findmyKOL
Clinical trialNCT04855617CompletedObservational

Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

SponsorNYU Langone HealthEnrollment122Multiple Sclerosis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is designed to determine whether symptom burden differs by time to infusion.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Elliot Lewis Center for Multiple Sclerosis Care

    Wellesley, Massachusetts, United States

  • Nyu Langone Health Multiple Sclerosis Comprehensive Care Center (nyulh Msccc)

    New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ocrelizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 Oct 2020
Primary completion
1 Oct 2022
Completion
1 Oct 2022
Last update posted
15 Jun 2023
Registered enrollment
122
Registry id
NCT04855617
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.